Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.09B |
| 2 |
K
Kellanova
K
|
+$912M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$774M |
| 4 |
Wells Fargo
WFC
|
+$717M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$604M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$1.36B |
| 2 |
Canadian Natural Resources
CNQ
|
+$927M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$922M |
| 4 |
Crown Castle
CCI
|
+$857M |
| 5 |
McKesson
MCK
|
+$825M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.44% |
| 2 | Technology | 15.01% |
| 3 | Financials | 11.47% |
| 4 | Consumer Discretionary | 10.69% |
| 5 | Communication Services | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Paychex
PAYX
$43.2B
| $58.9M | 0.02% |
1,000,000
| – | – |
|
327
SBA Communications
SBAC
$19.6B
| $58.9M | 0.02% |
489,000
| – | – |
|
|
PPL
328
PPL Corp
PPL
$26.8B
| $56.9M | 0.02% |
1,522,150
| – | – |
|
329
Centene
CNC
$32.9B
| $56.5M | 0.02% |
1,586,000
+592,000
| +60% | +$19.8M |
|
330
Carlisle Companies
CSL
$14.9B
| $55.2M | 0.02% |
519,000
| – | – |
|
331
Petrobras Class A
PBR.A
$103B
| $55M | 0.02% |
5,965,319
+3,212
| +0.1% | +$30.6K |
|
332
Alexandria Real Estate Equities
ARE
$8.32B
| $54.2M | 0.02% |
490,000
-375,283
| -43% | -$42.4M |
|
|
LGF.B
333
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $54M | 0.02% |
2,215,063
-1,165,687
| -34% | -$29.6M |
|
|
WMGI
334
DELISTED
Wright Medical Group Inc
WMGI
| $53.7M | 0.02% |
+1,725,000
| New | +$46.8M |
|
335
Artivion
AORT
$1.37B
| $52M | 0.02% |
3,121,286
+289,857
| +10% | +$5.12M |
|
336
Sherwin-Williams
SHW
$87.6B
| $51.5M | 0.02% |
498,000
| – | – |
|
337
Pfizer
PFE
$152B
| $51.3M | 0.02% |
1,581,000
| – | – |
|
338
Snap
SNAP
$8.81B
| $51.3M | 0.02% |
+2,277,450
| New | +$50.5M |
|
339
Cognex
CGNX
$10.3B
| $50.5M | 0.02% |
1,202,404
-420,000
| -26% | -$15.4M |
|
340
Integra LifeSciences
IART
$1.44B
| $50.2M | 0.02% |
1,191,800
-671,000
| -36% | -$28.7M |
|
341
BP
BP
$110B
| $49.8M | 0.02% |
1,652,983
-2
| -0% | -$61 |
|
342
United Parcel Service
UPS
$89.1B
| $49.4M | 0.02% |
460,000
| – | – |
|
343
Royal Caribbean
RCL
$82.6B
| $49.1M | 0.02% |
500,000
| – | – |
|
344
CONMED
CNMD
$1.49B
| $48.1M | 0.02% |
1,083,000
-167,719
| -13% | -$7.21M |
|
|
X
345
DELISTED
US Steel
X
| $48.1M | 0.02% |
1,422,050
-220,688
| -13% | -$7.84M |
|
|
CY
346
DELISTED
Cypress Semiconductor
CY
| $45.4M | 0.01% |
3,300,000
-2,933,000
| -47% | -$37.5M |
|
347
Old Republic International
ORI
$10.3B
| $45.1M | 0.01% |
2,200,800
| – | – |
|
348
iRhythm Holdings
IRTC
$4.1B
| $44.4M | 0.01% |
1,180,600
| – | – |
|
|
B
349
Barrick Mining
B
$67.3B
| $43M | 0.01% |
2,265,661
+2,910
| +0.1% | +$53.7K |
|
|
SIOX
350
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $42.3M | 0.01% |
354,322
-190,531
| -35% | -$20M |
|
Similar funds
Capital Research Global Investors's Q1 2017 Portfolio in Review
As of Q1 2017, Capital Research Global Investors held 457 positions worth $317B, up 2.8% from $308B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Research Global Investors withdrew a net $10.5B in Q1 2017, closing 32 positions and reducing 150 holdings. Its most notable exit was Spectra Energy Corp Wi, an estimated $395M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Technology and Financials.
Against the trend, Capital Research Global Investors opened a new position in TransDigm Group worth $346M.
- Capital Research Global Investors's largest Q1 2017 buy was TransDigm Group: 1,570,000 shares worth $346M.
- Capital Research Global Investors added most to Abbott in Q1 2017, an estimated $1.09B increase.
- Capital Research Global Investors's biggest Q1 2017 reduction was Amgen, cutting an estimated $1.36B.
- Capital Research Global Investors fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $395M.
- Capital Research Global Investors's ten largest holdings make up 24% of its $317B portfolio in Q1 2017.
- Capital Research Global Investors opened 30 new positions and closed 32 in Q1 2017.
- Capital Research Global Investors's portfolio value rose 2.8% quarter-over-quarter to $317B.
Based on Capital Research Global Investors's 13F filing for Q1 2017, filed 15 May 2017.